Cardiff Oncology to present preclinical data on onvansertib

Cardiff Oncology (CRDF) will present new preclinical data in a poster at the American Association for Cancer Research Annual Meeting, taking place April 17-22 in San Diego, California. These data highlight the potential of Cardiff’s highly specific oral PLK1 inhibitor, onvansertib, in combination with the HER2-targeted antibody-drug conjugate, trastuzumab deruxtecan, demonstrating robust antitumor activity and the ability to overcome resistance in HER2-low breast cancer models. “These preclinical findings highlight a potential new opportunity for onvansertib, demonstrating its ability to enhance the activity of ADCs, which are becoming mainstays in oncology across multiple indications,” said Tod Smeal, Chief Scientific Officer of Cardiff Oncology. “By enhancing and prolonging DNA damage, this combination appears to drive greater apoptosis than either agent alone, offering a promising new approach for patients whose cancers have become resistant to standard-of-care treatments.”